ClinicalTrials.gg
Sign In

Hematologic Diseases clinical trials

The registry lists 609 studies for Hematologic Diseases across more than 10 countries. 108 are recruiting or about to start. 169 of them are mainly about Hematologic Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 122 narrower conditions too, such as Multiple Myeloma: 22,904 studies, 4,786 open.

ClinicalTrials.gov finds 22,479 studies for Hematologic Diseases. How that becomes 609 here

This page counts the studies the registry files under Hematologic Diseases, and those it files under no condition that list Hematologic Diseasesthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 22,479Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −21,248Filed under a narrower condition, counted on its own pageMultiple Myeloma 3,618 · Leukemia, Myeloid, Acute 3,205 · Precursor Cell Lymphoblastic Leukemia-Lymphoma 1,596 · Anemia 1,520 · Leukemia 1,171 · Leukemia, Lymphocytic, Chronic, B-Cell 1,028 · 104 more
  3. −1List Hematologic Diseases as a condition, but the registry did not file them under itMost often written as “Malignant Hematological Diseases” (1). The registry filed them under other conditions only, most often Bronchiolitis Obliterans Syndrome (1).
  4. −621Match it another way15 name it in the title, 1 in a keyword, and 605 by a synonym or other text the search reads.
  5. 609The count on this page6 of them list Hematologic Diseases in their own words; the registry filed them under no condition.

Get an email when these change. Save the Hematologic Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
328
Recruiting
72
Terminated
59
Status unknown
52
Active, not recruiting
35
Not yet recruiting
26

Phase

Phase 2
172
Phase 1
109
Phase 3
94
Phase 4
18
Early Phase 1
8

Where

United States
298
Italy
81
France
81
Germany
73
United Kingdom
70
Canada
68

Who runs them

National Heart, Lung, and Blood Institute (NHLBI) (42) · Seagen Inc. (30) · M.D. Anderson Cancer Center (14) · National Center for Research Resources (NCRR) (12) · Novartis Pharmaceuticals (11) · BioMarin Pharmaceutical (8) · Nanfang Hospital, Southern Medical University (7) · Pfizer (7)

What is being tested here

Drugs under test in Hematologic Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Cyclophosphamide4118
Dexamethasone417
Fludarabine3010
Busulfan2110
Lenalidomide238
Exagamglogene autotemcel266
Daratumumab202
Pomalidomide202
Mezagitamab222
Fludarabine phosphate202

Drug classes tested here Alkylating agents 4 open · Corticosteroids 4 open · Tyrosine kinase inhibitors (TKIs) 3 open · Antimetabolites 3 open · JAK inhibitors 1 open

Coming up

23phase 3 studies under way
36studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 72 Hematologic Diseases studies recruiting now, 46 (64%) set no upper age limit and 22 (31%) stop at 75 or younger. 27 (38%) take children under 18. 1 (1%) are for women only and 2 (3%) for men only; 4 (6%) take healthy volunteers.

Recruiting studies that take each age, of 72
AgeWomenMen
1018 (25%)19 (26%)
1868 (94%)69 (96%)
3066 (92%)67 (93%)
4062 (86%)63 (88%)
5061 (85%)62 (86%)
6557 (79%)57 (79%)
7552 (72%)52 (72%)
8548 (67%)48 (67%)

Across all 609 studies, recruiting or not: 31% stop at 75 or younger and 22% at 65; 42% take children; 1% are for women only and 7% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hematologic Diseases studies take

Of 49 phase 3 interventional studies under Hematologic Diseases, half reached primary completion within 37 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 126 mo16–74 · 33 studies——
Phase 247 mo33–94 · 41 studies——
Phase 337 mo25–66 · 49 studies37 mo25–66 · 44 studies—
Interventional, no phase37 mo22–47 · 54 studies—37 mo22–49 · 51 studies
Observational51 mo16–78 · 64 studies—45 mo13–190 · 47 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting2

Stopped2

Newly registered5

Studies

Recruiting first, then most recently updated. Showing 50 of 609. Browse all 609 → or search them.